Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2027

Conditions
Leukemia, Myeloid, AcuteRelapsed Adult AMLRefractory Leukemia
Interventions
DRUG

venetoclax combining chidamide and azacitidine (VCA)

information already included in arm/group descriptions

Trial Locations (1)

361003

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
collaborator

Fujian Provincial Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Zhangzhou manicipal hospital of Fujian Province

UNKNOWN

collaborator

Jieyang People's Hospital

OTHER

collaborator

Dongguan People's Hospital

OTHER_GOV

collaborator

Huizhou Municipal Central Hospital

OTHER

lead

The First Affiliated Hospital of Xiamen University

OTHER